Signature for Precise Chemosensitivity Prediction in PDAC
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Chemotherapy
- Registration Number
- NCT06461598
- Lead Sponsor
- Ruijin Hospital
- Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) is largely heterogeneous. We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC. Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3K/AKT/mTOR pathway markers were examined in consecutive patients with PDAC. A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model, and validated in two independent cohorts.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 365
Inclusion Criteria
- ECOG performance status score of 0-1 before resection
- complete clinicopathologic and follow-up data
- availability of formalin-fixed paraffin-embedded (FFPE) specimens of resected primary tumor and hematoxylin and eosin slides with invasive tumor components
Exclusion Criteria
- any previous history of cancer
- any anticancer therapy prior to resection or adjuvant radiotherapy
- metastatic cases
- major postsurgical complications with Clavien-Dindo Grade ≥2
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Training cohort Chemotherapy - Validation cohort Chemotherapy -
- Primary Outcome Measures
Name Time Method Overall survival 3-year Time between resection and death of any cause
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ruijin Hospital
🇨🇳Shanghai, China